Loading...
•
Sep 27, 2020
Pfizer Q3 2020 Earnings Report
Reported third-quarter results, driven by biopharma operational growth and key brands performance.
Key Takeaways
Pfizer reported a decrease in third-quarter revenues by 4% to $12.1 billion. Despite the decline, Biopharma revenues increased by 4% operationally, driven by Vyndaqel/Vyndamax, biosimilars, and key brands like Eliquis and Ibrance. The company updated and tightened its 2020 financial guidance, including a slight increase to the midpoint of Adjusted Diluted EPS.
Third-Quarter 2020 Revenues of $12.1 Billion; Reported Diluted EPS of $0.39, Adjusted Diluted EPS of $0.72
4% Operational Growth from Biopharma, Primarily Driven by the Ongoing Strong Performance of Vyndaqel/Vyndamax, Growth from our Leading Portfolio of Biosimilars, as Well as Continued Strength from Key Brands Including Eliquis, Ibrance, Xeljanz, Inlyta and Xtandi
Updated and Tightened Ranges for Certain Components of Total Company 2020 Financial Guidance, Including a Slight Increase to the Midpoint of Adjusted Diluted EPS Guidance Range
Continue to Expect to Close the Upjohn Transaction with Mylan N.V. (Mylan) in the Fourth Quarter of 2020
Pfizer
Pfizer
Pfizer Revenue by Segment
Revenue by Segment
Biopharma Revenue
CapyFin.com Forward Guidance
Pfizer updated and tightened the ranges for certain components of Total Company 2020 financial guidance, including a slight increase to the midpoint of the Adjusted Diluted EPS guidance range, and reaffirmed all 2020 financial guidance components for New Pfizer and Upjohn.
Positive Outlook
- Revenues: $48.8 to $49.5 billion (previously $48.6 to $50.6 billion)
- Adjusted Cost of Sales as a Percentage of Revenues: 20.2% to 20.7% (previously 19.5% to 20.5%)
- Adjusted SI&A Expenses: $11.5 to $12.0 billion (previously $11.5 to $12.5 billion)
- Adjusted R&D Expenses: $8.8 to $9.1 billion (previously $8.6 to $9.0 billion)
- Adjusted Other (Income)/Deductions: Approximately $1.0 billion of income (previously approximately $800 million of income)
Challenges Ahead
- Financial guidance reflects management’s current expectations for operational performance, foreign exchange rates as well as various COVID-19-related uncertainties, primarily those related to the severity, duration and global macroeconomic impact of the pandemic.
- Key guidance assumptions regarding these uncertainties broadly reflect an ongoing, gradual global recovery from the macroeconomic and healthcare impacts of the COVID-19 pandemic.
- Current guidance continues to assume no revenue contributions from a potential COVID-19 vaccine.
- Financial guidance reflects the anticipated unfavorable impact of approximately $0.5 billion on revenues and approximately $0.04 on Adjusted diluted EPS as a result of changes in foreign exchange rates relative to the U.S. dollar compared to foreign exchange rates from 2019.
- Guidance for Adjusted diluted EPS assumes diluted weighted-average shares outstanding of approximately 5.6 billion shares, which assumes no share repurchases in 2020.